Datroway Ivonescimab Phase III Planned in First-Line TNBC
Datroway ivonescimab trials will start with a Phase III in first-line triple-negative breast cancer in a new AstraZeneca, Daiichi Sankyo and Summit pact.
Datroway ivonescimab trials will start with a Phase III in first-line triple-negative breast cancer in a new AstraZeneca, Daiichi Sankyo and Summit pact.